<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04032119</url>
  </required_header>
  <id_info>
    <org_study_id>EPI-ESD RCT01</org_study_id>
    <nct_id>NCT04032119</nct_id>
  </id_info>
  <brief_title>RCT of Gastric ESD With or Without Epineprhine Added Solution</brief_title>
  <official_title>Multicenter Randomized Controlled Trial of Gastric Endoscopic Submucosal Dissection With or Without Epineprhine Added Solution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Osaka International Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shizuoka Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fukuoka University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changi General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyoto 2nd Red Cross Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ishikawa Prefectural Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kosin University Gospel Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international multi-center randomised controlled study comparing outcomes of
      gastric endoscopic submucosal dissection (ESD) with or without addition of epinephrine in the
      submucosal injection solution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopic submucosal dissection (ESD) is an endoscopic technique aiming to achieve en-bloc
      resection of mucosal neoplastic lesion in the gastrointestinal tract. It is now considered as
      the standard of treatment for early gastric cancer confined to the mucosa, achieving an
      excellent overall survival comparable to that of surgical resection.

      Important adverse events associated with gastric ESD include hemorrhage (intraoperative or
      delayed) and perforation. The reported incidence of intraprocedural and delayed hemorrhage of
      gastric ESD is generally higher than that of esophageal or colorectal ESD5. This is likely
      due to the rich blood supply of the stomach penetrating from the muscularis to the submucosal
      layer. Bleeding during ESD would result in difficulty in visualizing the correct plane of
      dissection from blood clots obscuring view of the endoscope. As a result, prolonged
      procedural time may be required to achieve hemostasis and obtain adequate view for
      dissection.

      There are currently different options of the solution for submucosal injection during gastric
      ESD. Epineprhine has often been added into these solutions with the aim of causing
      vasoconstrictive effect and potentially reduce bleeding during the procedure. The use of
      epinephrine has been recommended when removing larger pedunculated polyps with endoscopic
      mucosal resection (EMR)6. However the exact clinical benefit of adding epinephrine during
      gastric ESD has not been proven in the literature. On the other hand, when larger dose of
      epinephrine is absorbed systemically it may rarely cause significant tachycardia and
      generalized vasoconstriction, putting patients at risk of myocardial infarction or
      cerebrovascular accident.

      A retrospective propensity score analysis was previously performed in one of our Japanese
      center (Presented at JGCA 2019, Shizuoka). After adjustment of important confounding factors
      including age, sex, tumor location, specimen size, depth of tumor invasion, presence of
      histological ulcer or scar and operators' experience, the addition of epinephrine into
      submucosal solution was associated with a significantly shorter procedural time upon
      multivariate analysis. The mean procedural time was 72±54 minutes versus 93±62 minutes with
      and without epinephrine respectively. (p&lt;0.001) With the encouraging result from a single
      center retrospective study, we plan to conduct a prospective multicenter randomized
      controlled study to confirm the benefit of adding epinephrine into the submucosal solution
      during gastric ESD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall procedural time</measure>
    <time_frame>During the endoscopic procedure</time_frame>
    <description>From the beginning of mucosal incision till the end of submucosal dissection, excluding time for prophylactic homeostasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of intra-procedural hemorrhage events</measure>
    <time_frame>During the endoscopic procedure</time_frame>
    <description>The number of oozing or spurting bleeding events during a procedure, requiring hemostasis with coagulating forceps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum systolic blood pressure</measure>
    <time_frame>During the endoscopic procedure</time_frame>
    <description>Maximum systolic blood pressure during ESD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum heart rate</measure>
    <time_frame>During the endoscopic procedure</time_frame>
    <description>Maximum heart rate during ESD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event - Delayed hemorrhage</measure>
    <time_frame>30 days</time_frame>
    <description>Delayed hemorrhage (Based on CTCAE definition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event - Perforation</measure>
    <time_frame>30 days</time_frame>
    <description>Perforation (Based on CTCAE definition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event - Cardiovascular event</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiovascular event (Based on CTCAE definition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event - Cerebrovascular event</measure>
    <time_frame>30 days</time_frame>
    <description>Cerebrovascular event (Based on CTCAE definition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other adverse event</measure>
    <time_frame>30 days</time_frame>
    <description>Based on CTCAE definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathology</measure>
    <time_frame>During the endoscopic procedure</time_frame>
    <description>Final histology based on Vienna Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of lesion</measure>
    <time_frame>During the endoscopic procedure</time_frame>
    <description>Size of lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of invasion</measure>
    <time_frame>During the endoscopic procedure</time_frame>
    <description>Depth of tumor invasion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vertical margin</measure>
    <time_frame>During the endoscopic procedure</time_frame>
    <description>Vertical margin involvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Horizontal margin</measure>
    <time_frame>During the endoscopic procedure</time_frame>
    <description>Horizontal margin involvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differentiation</measure>
    <time_frame>During the endoscopic procedure</time_frame>
    <description>Degree of differentiation for cancer of stomach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphovascular invasion</measure>
    <time_frame>During the endoscopic procedure</time_frame>
    <description>Lymphovascular invasion on pathology</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Gastric Neoplasm</condition>
  <condition>Early Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Epinephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2ml 1:10000 epinephrine diluted into each 20ml of the original solution for submucosal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No epinephrine would be added into the solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic submucosal dissection</intervention_name>
    <description>Endoscopic submucosal dissection</description>
    <arm_group_label>Epinephrine</arm_group_label>
    <arm_group_label>Non-epinephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>Epinephrine</description>
    <arm_group_label>Epinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Selection criteria: Presence of intramucosal neoplastic lesions in the stomach
             planning for endoscopic submucosal dissection (Vienna Classification Category 3 and 4
             lesion)

          -  Target subjects receiving sufficient briefing from the attending physician regarding
             the content of this study and providing informed consent for participation

        Exclusion Criteria:

          -  Recurrent / remnant lesion after previous endoscopic resection

          -  Lesions arising from surgical anastomotic site, such as gastrojejunostomy /
             gastroduodenostomy.

          -  Marked electrolyte abnormalities

          -  Hemostatic or coagulative abnormalities

          -  Patient on anti-coagulant agents, including warfarin and other direct oral
             anti-coagulants (those on antiplatelet can be included)

          -  Failure of vital organ (heart, lungs, liver, or kidneys) function

          -  Allergic to components of injection solutions: Epinephrine, hyaluronic acid etc

          -  Other cases deemed by the examining physician as unsuitable for safe treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hon Chi Yip, MBChB, FRCSEd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hon Chi Yip, MBChB, FRCSEd (Gen)</last_name>
    <phone>+85235052627</phone>
    <email>hcyip@surgery.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noriya Uedo, MD</last_name>
    <email>noriya.uedo@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hon Chi Yip, MBChB, FRCSEd (Gen)</last_name>
      <phone>+85235052627</phone>
      <email>hcyip@surgery.cuhk.edu.hk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ishikawa Prefecture Central Hospital</name>
      <address>
        <city>Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hisashi Doyama</last_name>
      <email>doyama.134@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyoto 2nd Red Cross Hospital</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Takuji Kawamura</last_name>
      <email>kawamura_takuji@yahoo.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noriya Uedo</last_name>
      <email>uedou-no@mc.pref.osaka.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kohei Takizawa</last_name>
      <email>k.takizawa@scchr.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyoungwon Jung</last_name>
      <email>forjkw@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Weiquan Li</last_name>
      <email>james.li.w.q@singhealth.com.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>July 4, 2020</last_update_submitted>
  <last_update_submitted_qc>July 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Hon Chi Yip</investigator_full_name>
    <investigator_title>Associate Consultant</investigator_title>
  </responsible_party>
  <keyword>Gastric Endoscopic submucosal dissection</keyword>
  <keyword>Epinephrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

